| Host: |
Mouse |
| Applications: |
WB |
| Reactivity: |
Transfected |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Mouse monoclonal antibody anti-Proto-oncogene Wnt-3 is suitable for use in Western Blot research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
4F11-H1-F4 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG1 |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from mouse ascites by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:1000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
WNT3 |
| Gene ID: |
7473 |
| Uniprot ID: |
WNT3_HUMAN |
| Specificity: |
Transfected Only. |
| Immunogen: |
Purified recombinant human Wnt3 protein fragments expressed in E.coli. |
| Function | Ligand for members of the frizzled family of seven transmembrane receptors (Probable). Functions in the canonical Wnt signaling pathway that results in activation of transcription factors of the TCF/LEF family. Required for normal gastrulation, formation of the primitive streak, and for the formation of the mesoderm during early embryogenesis. Required for normal formation of the apical ectodermal ridge. Required for normal embryonic development, and especially for limb development. |
| Protein Name | Proto-Oncogene Wnt-3Proto-Oncogene Int-4 Homolog |
| Database Links | Reactome: R-HSA-201681Reactome: R-HSA-3238698Reactome: R-HSA-373080 |
| Cellular Localisation | SecretedExtracellular SpaceExtracellular Matrix |
| Alternative Antibody Names | Anti-Proto-Oncogene Wnt-3 antibodyAnti-Proto-Oncogene Int-4 Homolog antibodyAnti-WNT3 antibodyAnti-INT4 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
